Search Results

ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go 16 employees later this month.

Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc® trial at University of California, Davis (“UC Davis”) Medical Center in Sacramento, California.

While many describe California as having a tough life sciences market, there’s some optimism that employment opportunities will improve soon, according to California Life Sciences President and CEO Mike Guerra.

For the first eight months of 2024, California had the most job postings live on BioSpace—37.7% more than Massachusetts. Last year, Massachusetts ranked No.1 for the same time period.

IO Biotech announced today that the University of California Davis Comprehensive Cancer Center has dosed the first patient in its investigator-initiated trial which aims to evaluate IO102-IO103, the company’s investigational immune-modulating cancer vaccine.

Biocom California, the association representing the California life science industry, released a new report showing California’s life science industry directly provides more than 465,000 jobs in the state and generates $414.2 billion in total business output.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.

The Regents of the University of California, on behalf of the University of California, Irvine, has entered into a definitive agreement with Tenet Healthcare Corporation to acquire Tenet’s Pacific Coast Network.